PXDNL and breast carcinoma: Similarly, breast cancer patients with increased PXDNL (p=0.00011) and SDC1 (p<0.0001), and decreased FBLN1 (p=0.033) and ADAMTS8 (p=0.00017) expression levels tended to have shorter disease-specific survival (DSS) time (Figure S2B).